New hope for hard-to-treat ovarian cancer: experimental combo enters phase 2 trial
NCT ID NCT06434610
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the experimental drug B013 to standard chemotherapy (paclitaxel) can help people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 90 participants will receive either the combination or a placebo plus chemotherapy. The main goal is to see if the combination delays cancer growth or death.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, China
-
Fudan University Shanghai Cancer center
RECRUITINGShanghai, China
-
Fujian Cancer Hospital
RECRUITINGFuzhou, China
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanning, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, China
-
Qilu Hospital of Shandong University
RECRUITINGJinan, China
-
Shananxi Provincial Cancer Hospital
RECRUITINGXi'an, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, China
-
The First Affiliated Hospital of Bengbu Medical University
RECRUITINGBengbu, China
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, China
-
The Obstetrics & Gynecology Hospital of Fudan University
RECRUITINGShanghai, China
-
The Second Hospital of Hebei Medical University
RECRUITINGShijiazhuang, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, China
-
XiangYa Hospital CentralSouth University
RECRUITINGChangsha, China
-
Yibin city second people's Hospital
RECRUITINGYibin, China
-
Yunnan Cancer Hospital
RECRUITINGKunming, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a custom vaccine train the body to fight ovarian cancer?
- Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
- Can a Two-Drug combo outsmart resistant ovarian cancer?
- Can a targeted drug boost standard ovarian cancer therapy?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a daily pill keep BRCA-Linked ovarian cancer at bay?